Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.18
ANAC's Cash to Debt is ranked lower than
71% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: 56.38 vs. ANAC: 2.18 )
Ranked among companies with meaningful Cash to Debt only.
ANAC' s Cash to Debt Range Over the Past 10 Years
Min: 0.48  Med: 3.12 Max: N/A
Current: 2.18
Equity to Asset 0.27
ANAC's Equity to Asset is ranked lower than
85% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ANAC: 0.27 )
Ranked among companies with meaningful Equity to Asset only.
ANAC' s Equity to Asset Range Over the Past 10 Years
Min: -11.16  Med: 0.27 Max: 0.71
Current: 0.27
-11.16
0.71
F-Score: 4
Z-Score: 20.36
M-Score: -0.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -70.31
ANAC's Operating margin (%) is ranked higher than
51% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. ANAC: -70.31 )
Ranked among companies with meaningful Operating margin (%) only.
ANAC' s Operating margin (%) Range Over the Past 10 Years
Min: -2252.61  Med: -102.77 Max: 537.02
Current: -70.31
-2252.61
537.02
Net-margin (%) -76.14
ANAC's Net-margin (%) is ranked higher than
50% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. ANAC: -76.14 )
Ranked among companies with meaningful Net-margin (%) only.
ANAC' s Net-margin (%) Range Over the Past 10 Years
Min: -2275.15  Med: -109.74 Max: 492.02
Current: -76.14
-2275.15
492.02
ROE (%) -110.90
ANAC's ROE (%) is ranked lower than
84% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. ANAC: -110.90 )
Ranked among companies with meaningful ROE (%) only.
ANAC' s ROE (%) Range Over the Past 10 Years
Min: -599.54  Med: -93.42 Max: 134.29
Current: -110.9
-599.54
134.29
ROA (%) -34.30
ANAC's ROA (%) is ranked lower than
57% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. ANAC: -34.30 )
Ranked among companies with meaningful ROA (%) only.
ANAC' s ROA (%) Range Over the Past 10 Years
Min: -216.67  Med: -49.56 Max: 75.94
Current: -34.3
-216.67
75.94
ROC (Joel Greenblatt) (%) -3138.57
ANAC's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -356.62 vs. ANAC: -3138.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANAC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5992.71  Med: -1899.62 Max: 6087.56
Current: -3138.57
-5992.71
6087.56
Revenue Growth (3Y)(%) 77.20
ANAC's Revenue Growth (3Y)(%) is ranked higher than
93% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.40 vs. ANAC: 77.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ANAC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -66  Med: -23.15 Max: 462.3
Current: 77.2
-66
462.3
EBITDA Growth (3Y)(%) -6.70
ANAC's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.10 vs. ANAC: -6.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANAC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.3  Med: -17.60 Max: 10.2
Current: -6.7
-63.3
10.2
EPS Growth (3Y)(%) -7.60
ANAC's EPS Growth (3Y)(%) is ranked lower than
54% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ANAC: -7.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANAC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -43.80 Max: 6.4
Current: -7.6
0
6.4
» ANAC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ANAC Guru Trades in Q2 2015

Steven Cohen 45,000 sh (New)
Joel Greenblatt 13,741 sh (New)
Paul Tudor Jones 9,834 sh (-8.56%)
Chuck Royce 159,500 sh (-43.94%)
» More
Q3 2015

ANAC Guru Trades in Q3 2015

Jim Simons 310,458 sh (New)
Steven Cohen 150,600 sh (+234.67%)
Joel Greenblatt Sold Out
Paul Tudor Jones 8,532 sh (-13.24%)
Chuck Royce 119,500 sh (-25.08%)
» More
Q4 2015

ANAC Guru Trades in Q4 2015

Jim Simons Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 125,500 sh (-16.67%)
Chuck Royce 58,500 sh (-51.05%)
» More
Q1 2016

ANAC Guru Trades in Q1 2016

George Soros 4,200 sh (New)
Jim Simons 94,058 sh (New)
Steven Cohen 928,440 sh (+639.79%)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ANAC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:TSRO, NAS:ACAD, OTCPK:SBMFF, NAS:TECH, NAS:UTHR, NAS:ICPT, OTCPK:BTGGF, NAS:ALNY, NAS:IONS, NAS:JUNO, NAS:CBPO, NYSE:XON, NAS:SGEN, OTCPK:SOLTF, NAS:LGND, NAS:KITE, NAS:OPHT, NAS:RARE, NAS:NKTR, NAS:GLPG » details
Traded in other countries:44A.Germany,
Anacor Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.

Guru Investment Theses on Anacor Pharmaceuticals Inc

Royce Funds Comments on Anacor Pharmaceuticals - Oct 12, 2015

Anacor Pharmaceuticals (ANAC) continues to benefit from the recent launch of its first commercial product, Kerydin, a topical antifungal medication, and positive top-line results from two pivotal Phase 3 studies of Crisaborole, a topical treatment for atopic dermatitis.



From "Staying Diversified in the Pursuit of Sustainable Growth - Royce Funds Commentary."



Check out Chuck Royce latest stock trades

Top Ranked Articles about Anacor Pharmaceuticals Inc

Royce Funds Comments on Anacor Pharmaceuticals Guru stock highlight
Anacor Pharmaceuticals (ANAC) continues to benefit from the recent launch of its first commercial product, Kerydin, a topical antifungal medication, and positive top-line results from two pivotal Phase 3 studies of Crisaborole, a topical treatment for atopic dermatitis. Read more...

Ratios

vs
industry
vs
history
P/B 99.80
ANAC's P/B is ranked lower than
99% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ANAC: 99.80 )
Ranked among companies with meaningful P/B only.
ANAC' s P/B Range Over the Past 10 Years
Min: 2.43  Med: 17.86 Max: 174.59
Current: 99.8
2.43
174.59
P/S 51.75
ANAC's P/S is ranked lower than
77% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 12.56 vs. ANAC: 51.75 )
Ranked among companies with meaningful P/S only.
ANAC' s P/S Range Over the Past 10 Years
Min: 0.3  Med: 30.25 Max: 128.83
Current: 51.75
0.3
128.83
Current Ratio 6.29
ANAC's Current Ratio is ranked higher than
60% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. ANAC: 6.29 )
Ranked among companies with meaningful Current Ratio only.
ANAC' s Current Ratio Range Over the Past 10 Years
Min: 0.4  Med: 3.28 Max: 9.58
Current: 6.29
0.4
9.58
Quick Ratio 6.18
ANAC's Quick Ratio is ranked higher than
61% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ANAC: 6.18 )
Ranked among companies with meaningful Quick Ratio only.
ANAC' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 3.28 Max: 9.58
Current: 6.18
0.4
9.58
Days Inventory 252.96
ANAC's Days Inventory is ranked lower than
80% of the 442 Companies
in the Global Biotechnology industry.

( Industry Median: 128.95 vs. ANAC: 252.96 )
Ranked among companies with meaningful Days Inventory only.
ANAC' s Days Inventory Range Over the Past 10 Years
Min: 247.04  Med: 411.81 Max: 576.58
Current: 252.96
247.04
576.58
Days Sales Outstanding 64.46
ANAC's Days Sales Outstanding is ranked lower than
52% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.68 vs. ANAC: 64.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANAC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.43  Med: 34.47 Max: 175.51
Current: 64.46
1.43
175.51
Days Payable 319.42
ANAC's Days Payable is ranked higher than
88% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 57.78 vs. ANAC: 319.42 )
Ranked among companies with meaningful Days Payable only.
ANAC' s Days Payable Range Over the Past 10 Years
Min: 522.22  Med: 1296.12 Max: 2070.01
Current: 319.42
522.22
2070.01

Valuation & Return

vs
industry
vs
history
Price/Net Cash 275.56
ANAC's Price/Net Cash is ranked lower than
99% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 4.94 vs. ANAC: 275.56 )
Ranked among companies with meaningful Price/Net Cash only.
ANAC' s Price/Net Cash Range Over the Past 10 Years
Min: 2.95  Med: 20.00 Max: 294.28
Current: 275.56
2.95
294.28
Price/Net Current Asset Value 118.10
ANAC's Price/Net Current Asset Value is ranked lower than
98% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. ANAC: 118.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ANAC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.8  Med: 17.24 Max: 109.68
Current: 118.1
2.8
109.68
Price/Tangible Book 100.20
ANAC's Price/Tangible Book is ranked lower than
99% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ANAC: 100.20 )
Ranked among companies with meaningful Price/Tangible Book only.
ANAC' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.67  Med: 16.19 Max: 96.72
Current: 100.2
2.67
96.72
Price/Median PS Value 1.71
ANAC's Price/Median PS Value is ranked lower than
80% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. ANAC: 1.71 )
Ranked among companies with meaningful Price/Median PS Value only.
ANAC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.81 Max: 2.58
Current: 1.71
0.01
2.58
Earnings Yield (Greenblatt) (%) -1.40
ANAC's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 1104 Companies
in the Global Biotechnology industry.

( Industry Median: -9.68 vs. ANAC: -1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANAC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.4  Med: 12.35 Max: 18.3
Current: -1.4
-1.4
18.3

More Statistics

Revenue (TTM) (Mil) $84.63
EPS (TTM) $ -1.46
Short Percentage of Float16.96%
52-Week Range $52.00 - 156.93
Shares Outstanding (Mil)45.37

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 77 390 859
EPS ($) -1.34 3.39 7.45
EPS w/o NRI ($) -1.34 3.39 7.45
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ANAC

Headlines

Articles On GuruFocus.com
Royce Smaller-Companies Growth Fund Annual Letter Mar 19 2016 
Royce Funds Comments on Anacor Pharmaceuticals Oct 12 2015 
Staying Diversified in the Pursuit of Sustainable Growth - Royce Funds Commentary Oct 12 2015 
Royce Smaller-Companies Growth Fund Shareholder Letter Sep 20 2015 
Panic-Proofing the Small Investor Aug 26 2015 
Anacor Pharmaceuticals’ Q4 Was A Solid One For Investors Mar 16 2015 
Paulson Bets Again On Mallinckrodt Aug 07 2014 
3 Great Dividend Stocks at All-Time Highs Aug 19 2013 
Weekly CFO Buys Highlight Aug 19 2013 
Senior Vice President and CFO of Anacor Pharmaceuticals Inc. Geoffrey Parker Bought 43,046 Shares Jun 20 2013 

More From Other Websites
Will Pfizer Book Another Healthy Quarter? Jul 22 2016
What Can We Expect from the Pfizer-Anacor Deal? Jul 06 2016
The Pfizer-Anacor Deal Wrapped Up in June: Now What? Jul 06 2016
Pfizer Completes Anacor Acquisition Jun 24 2016
Pfizer Completes Acquisition Of Anacor Jun 24 2016
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Jun 24 2016
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run Jun 23 2016
Will A New Suitor For Anacor Emerge? Jun 15 2016
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jun 08 2016
How Wellcome and Gates charities profit from helping biotech May 30 2016
How Wellcome and Gates charities profit from helping biotech May 30 2016
How Wellcome and Gates charities profit from helping biotech May 30 2016
Anacor received rival bid before Pfizer deal - filing May 26 2016
Anacor received rival bid before Pfizer deal - filing May 26 2016
Anacor reveals receiving rival bid before Pfizer deal - filing May 26 2016
Buy Pfizer, Chevron, Newell Brands and Enjoy the Profits May 25 2016
Why Pfizer, Chevron and Newell Brands Could be Great For Your Portfolio May 25 2016
XBI’s and IHI’s Mid-Caps Soared, Overturning 2 Weeks of Losses May 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)